Pre-operative Chemotherapy in Operable Breast Cancer, Phase III Study Comparing a Short Intensive Pre-operative Chemotherapy With the Same Therapy Initiated Shortly After Surgery(Peri-operatively)(POCOB)EORTC 10902)
This study is ongoing, but not recruiting participants.
Sponsor:
King Faisal Specialist Hospital & Research Center
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:
NCT00544505
First received: October 15, 2007
Last updated: December 11, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Pre-operative chemotherapy in operable breast cancer, phase III study comparing a short intensive pre-operative chemotherapy with the same therapy initiated shortly after surgery (peri-operatively) (POCOB) (EORTC 10902)
| Condition | Intervention |
|---|---|
|
Breast Cancer |
Drug: Fluorouracil/Epirubicin/Cyclophosphamide |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by King Faisal Specialist Hospital & Research Center:
Primary Outcome Measures:
- Efficacy [ Time Frame: overall ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 10 |
| Study Start Date: | September 2007 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | September 2012 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Fluorouracil/Epirubicin/Cyclophosphamide
Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
Eligibility| Ages Eligible for Study: | up to 70 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Disease Characteristics:
- Palpable, operable breast cancer that has been diagnosed by core needle biopsy (mandatory for T1c tumors) or fine needle aspiration within 21 days prior to entry
- Stage T1c-4b, N0-1, M0
Hormone receptor status:
- Not specified
- No bilateral breast cancer
Prior/Concurrent Therapy:
- No previous treatment for breast cancer
Biologic therapy:
- Not specified
Chemotherapy:
- No previous chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- Not specified
Surgery:
- Core needle biopsy or fine needle aspiration within 21 days prior to entry
- Repeated core needle biopsy permitted
Patient Characteristics:
Age:
- 16 to 70
Sex:
- Women only
Menopausal status:
- Not specified
Performance status:
- WHO 0-2
Hematopoietic:
- WBC at least 4,000
- Platelets at least 100,000
Hepatic:
- Bilirubin no greater than 2.8 mg/dL (50 micromoles/L)
Renal:
- Creatinine no greater than 1.3 mg/dL (120 micromoles/L)
Cardiovascular:
- No congestive heart failure
- No significant arrhythmia
- No bilateral bundle branch block
- No recent myocardial infarction
- No uncontrolled hypertension (diastolic pressure greater than 110 mm Hg)
Other:
- No male breast cancer
- No pregnant or nursing women
No second malignancy except adequately treated:
- Nonmelanomatous skin cancer
- Cervical cancer
Contacts and Locations
More Information
No publications provided
| Responsible Party: | King Faisal Specialist Hospital & Research Center |
| ClinicalTrials.gov Identifier: | NCT00544505 History of Changes |
| Other Study ID Numbers: | RAC#931-006 |
| Study First Received: | October 15, 2007 |
| Last Updated: | December 11, 2011 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Cyclophosphamide Fluorouracil Epirubicin Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |
Pharmacologic Actions Antirheumatic Agents Therapeutic Uses Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antibiotics, Antineoplastic Antimetabolites Antimetabolites, Antineoplastic |
ClinicalTrials.gov processed this record on June 13, 2013